{"id":"W2550644244","doi":"10.1136/annrheumdis-2016-eular.3359","title":"THU0140 Efficacy and Safety Analysis by Overall anti-Drug Antibody Results Up To Week 30 in Patients with Rheumatoid Arthritis Treated with Sb2 (An Infliximab Biosimilar) or Infliximab Reference Product in Phase III Study","year":2016,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Rheumatoid arthritis; Biosimilar; Infliximab; Internal medicine; Methotrexate; Immunogenicity; Gastroenterology; Clinical efficacy; Safety profile; Drug; Surgery; Antibody; Adverse effect; Pharmacology; Immunology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006387439,0.0004322675,0.001263284,0.0003683914,0.0001351419,0.00004114023,0.0004728235,0.0001018642,0.0001486786],"category_scores_gemma":[0.0006919315,0.0002000102,0.00009088154,0.001096394,0.0004344558,0.0002792857,0.0001890088,0.000174911,0.000005229327],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002634407,"about_ca_system_score_gemma":0.00009493505,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005823613,"about_ca_topic_score_gemma":0.0005150485,"domain_scores_codex":[0.9965032,0.0009004158,0.001069062,0.0007823145,0.0002054946,0.0005395573],"domain_scores_gemma":[0.9977795,0.0004919122,0.0004446913,0.0009301407,0.0002222406,0.0001315371],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06094998,0.02041197,0.8406995,0.0001054095,0.003375405,0.00001606607,0.002137834,0.00004013323,0.001719456,0.00004304908,0.001957535,0.06854367],"study_design_scores_gemma":[0.04139036,0.003615108,0.9479499,0.001611761,0.0003342206,0.000002337844,0.0003462873,0.00001498914,0.003942147,0.00002862711,0.0002665207,0.0004977192],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952124,0.0008894654,0.00001944672,0.001007044,0.00003522024,0.001479289,0.001299199,0.00003445727,0.00002344398],"genre_scores_gemma":[0.998199,0.00116675,0.00006620648,0.0001913993,0.000002538831,0.00003843407,0.0001407889,0.00002359804,0.000171254],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1072504,"threshold_uncertainty_score":0.815618,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02680917179020043,"score_gpt":0.3187931148104403,"score_spread":0.2919839430202399,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}